MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 07-31-2025
Bio-Rad Laboratories Gross Profit 2011-2026 | BIO
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit Bio-Rad Laboratories
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 342 M | 366 M | 1.57 B | 1.64 B | 1.44 B | 1.26 B | 1.22 B | 1.19 B | 1.14 B | 1.12 B | 1.18 B | 1.18 B | 1.15 B | 1.18 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.64 B | 342 M | 1.14 B |
Quarterly Gross Profit Bio-Rad Laboratories
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 345 M | 306 M | 356 M | 355 M | 326 M | 336 M | 362 M | 362 M | - | 373 M | 395 M | 403 M | 401 M | 437 M | 402 M | 401 M | 460 M | 367 M | 293 M | 317 M | 330 M | 307 M | 308 M | 312 M | 333 M | 287 M | 302 M | 302 M | 345 M | 299 M | 273 M | 270 M | 314 M | 280 M | 280 M | 264 M | 308 M | 264 M | 280 M | 270 M | 317 M | 289 M | 297 M | 275 M | 323 M | 284 M | 300 M | 271 M | 314 M | 274 M | 288 M | 279 M | 311 M | 296 M | 293 M | 278 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 460 M | 264 M | 320 M |
Gross Profit of other stocks in the Medical devices industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Align Technology
ALGN
|
2.8 B | $ 176.83 | 5.97 % | $ 13.2 B |  USA |
 |
Alphatec Holdings
ATEC
|
532 M | $ 11.66 | 5.71 % | $ 1.75 B | USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
67.9 M | - | - | $ 1.77 B | USA |
 |
Acutus Medical
AFIB
|
-3.14 M | - | -26.83 % | $ 2.62 M | USA |
 |
AxoGen
AXGN
|
167 M | $ 34.0 | 9.71 % | $ 1.57 B | USA |
 |
AdaptHealth Corp.
AHCO
|
89.3 M | $ 12.18 | 2.01 % | $ 1.65 B | USA |
 |
Allied Healthcare Products
AHPI
|
443 K | - | 3.58 % | $ 2.21 M | USA |
 |
Conformis
CFMS
|
23.2 M | - | - | $ 16.4 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
584 K | - | -5.86 % | $ 30.6 M | USA |
 |
Cardiovascular Systems
CSII
|
173 M | - | 0.15 % | $ 844 M | USA |
 |
Cytosorbents Corporation
CTSO
|
26.5 M | $ 0.62 | 1.67 % | $ 38.6 M | USA |
 |
Bruker Corporation
BRKR
|
1.65 B | $ 38.25 | 4.31 % | $ 5.7 K | USA |
 |
Boston Scientific Corporation
BSX
|
13.9 B | $ 62.56 | 1.15 % | $ 92.6 B | USA |
 |
Dynatronics Corporation
DYNT
|
6.01 M | - | 14.99 % | $ 929 K | USA |
 |
Apollo Endosurgery
APEN
|
42.4 M | - | - | $ 475 M | USA |
 |
Electromed
ELMD
|
50 M | $ 24.4 | 2.61 % | $ 206 M | USA |
 |
Second Sight Medical Products
EYES
|
500 K | - | -0.97 % | $ 54.4 M | USA |
 |
ClearPoint Neuro
CLPT
|
22.7 M | $ 9.17 | 1.1 % | $ 260 M | USA |
 |
GBS
GBS
|
1.25 M | - | -0.57 % | $ 7.12 M | USA |
 |
Globus Medical
GMED
|
719 M | $ 91.96 | 2.13 % | $ 12.4 B | USA |
 |
CryoLife, Inc.
CRY
|
168 M | - | -4.14 % | $ 702 M | USA |
 |
Avinger
AVGR
|
2 M | - | -20.74 % | $ 369 K | USA |
 |
Inogen
INGN
|
154 M | $ 6.67 | -1.91 % | $ 177 M | USA |
 |
Inspire Medical Systems
INSP
|
779 M | $ 53.38 | -1.89 % | $ 1.57 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
198 M | - | - | $ 3.31 B | USA |
 |
IRIDEX Corporation
IRIX
|
19.2 M | $ 1.03 | - | $ 17.4 M | USA |
 |
Integer Holdings Corporation
ITGR
|
500 M | $ 87.48 | 2.78 % | $ 3.04 B | USA |
 |
Invacare Corporation
IVC
|
48.3 M | - | - | $ 24.7 M | USA |
 |
Aziyo Biologics
AZYO
|
6.6 M | - | 1.37 % | $ 20.5 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
173 M | $ 16.01 | 1.59 % | $ 376 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
28.7 M | - | 0.03 % | $ 1.58 B |  Israel |
 |
Misonix, Inc.
MSON
|
43.7 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
1.99 M | - | - | $ 111 M |  Canada |
 |
LivaNova PLC
LIVN
|
940 M | $ 64.66 | 1.76 % | $ 3.53 B |  Britain |
 |
LENSAR
LNSR
|
14.1 M | $ 5.53 | -1.78 % | $ 66.1 M | USA |
 |
Butterfly Network
BFLY
|
48.8 M | $ 4.14 | 2.22 % | $ 876 M | USA |
 |
Intersect ENT, Inc.
XENT
|
50.2 M | - | - | $ 955 M | USA |
 |
EDAP TMS S.A.
EDAP
|
24.4 M | $ 3.37 | -0.88 % | $ 126 M |  France |
 |
Myomo
MYO
|
26.9 M | $ 0.68 | 0.44 % | $ 28.5 M | USA |
 |
NanoVibronix
NAOV
|
1.51 M | - | - | $ 1.08 M | USA |
 |
BIOLASE
BIOL
|
16.7 M | - | -13.19 % | $ 166 K | USA |
 |
Delcath Systems
DCTH
|
73.4 M | $ 9.85 | 1.86 % | $ 353 M | USA |
 |
BioSig Technologies
BSGM
|
229 K | - | 37.08 % | $ 85.7 M | USA |
 |
Natus Medical Incorporated
NTUS
|
274 M | - | 1.94 % | $ 1.05 B | USA |
 |
Nevro Corp.
NVRO
|
270 M | - | - | $ 217 M | USA |